Literature DB >> 17957724

Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells.

Shoichiro Ohta1, Edwin W Lai, John C Morris, Alan L Y Pang, Morihiro Watanabe, Hiroshi Yazawa, Richard Zhang, Jeffery E Green, Wai-Yee Chan, Paul Sirajuddin, Shun'ichiro Taniguchi, James F Powers, Arthur S Tischler, Karel Pacak.   

Abstract

The development of metastatic cancer is associated with overexpression or downregulation of specific genes and cell regulatory pathways. Some of these genes and pathways may be involved in invasion and dissemination of tumor cells, while others may promote seeding, survival or growth of cells at specific distant sites. In this investigation, gene expression profiles of nonmetastasizing tumors generated by injecting mouse pheochromocytoma cells (MPCs) subcutaneously were compared to those of liver tumors generated by injecting the cells intravenously. Both were compared to the cultured parental cell line. Tumors in the liver have a route of spread, anatomical distribution, and growth environment similar to naturally metastasizing pheochromocytomas, while intravenous injection of cells bypasses the initial steps of metastasis occurring spontaneously from a primary tumor. Eight genes were upregulated in liver tumors, 15 in subcutaneous tumors and seven in both compared to the cultured cells. Using quantitative real-time PCR, expression of five genes (Metap2, Reck, S100a4, Timp2, and Timp3) was verified as significantly lower in liver tumors than in subcutaneous tumors. Downregulation of these genes has been previously been associated with malignancy of pheochromocytomas. These findings indicate that different microenvironments can differentially affect the expression of metastasis-related genes in pheochromocytomas, and that overexpression or underexpression of these genes need not be present when the tumor cells are initially disseminated. The hepatic localization of tumors formed by intravenously injected MPC cells and the tumors' gene expression profile resembling that of naturally occurring pheochromocytoma metastases support the use of this model to study pheochromocytoma metastasis. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 17957724     DOI: 10.1002/mc.20388

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  10 in total

1.  Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.

Authors:  Lucia Martiniova; Shiromi M Perera; Frederieke M Brouwers; Salvatore Alesci; Mones Abu-Asab; Amanda F Marvelle; Dale O Kiesewetter; David Thomasson; John C Morris; Richard Kvetnansky; Arthur S Tischler; James C Reynolds; Antonio Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2011-01-13       Impact factor: 5.678

Review 2.  Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis.

Authors:  Charlotte Lussey-Lepoutre; Alexandre Buffet; Aurélie Morin; Judith Goncalves; Judith Favier
Journal:  Cell Tissue Res       Date:  2018-02-09       Impact factor: 5.249

3.  Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology.

Authors:  Junjie Li; Feng Chen; Yuanbo Feng; Marlein Miranda Cona; Jie Yu; Alfons Verbruggen; Jian Zhang; Raymond Oyen; Yicheng Ni
Journal:  Transl Oncol       Date:  2013-02-01       Impact factor: 4.243

4.  In vivo fluorescence imaging and urinary monoamines as surrogate biomarkers of disease progression in a mouse model of pheochromocytoma.

Authors:  Martin Ullrich; Ralf Bergmann; Mirko Peitzsch; Marc Cartellieri; Nan Qin; Monika Ehrhart-Bornstein; Norman L Block; Andrew V Schally; Jens Pietzsch; Graeme Eisenhofer; Stefan R Bornstein; Christian G Ziegler
Journal:  Endocrinology       Date:  2014-08-19       Impact factor: 4.736

5.  Regulation of cell invasion and signalling pathways in the pituitary adenoma cell line, HP-75, by reversion-inducing cysteine-rich protein with kazal motifs (RECK).

Authors:  Daizo Yoshida; Ryutaro Nomura; Akira Teramoto
Journal:  J Neurooncol       Date:  2008-05-21       Impact factor: 4.130

6.  Noninvasive monitoring of a murine model of metastatic pheochromocytoma: a comparison of contrast-enhanced microCT and nonenhanced MRI.

Authors:  Lucia Martiniova; Melanie S Kotys; David Thomasson; Daniel Schimel; Edwin W Lai; Marcelino Bernardo; Maria J Merino; James F Powers; Jan Ruzicka; Richard Kvetnansky; Peter L Choyke; Karel Pacak
Journal:  J Magn Reson Imaging       Date:  2009-03       Impact factor: 4.813

7.  Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature.

Authors:  Lucia Martiniova; Edwin W Lai; Abdel G Elkahloun; Mones Abu-Asab; Andrea Wickremasinghe; Daniel C Solis; Shiromi M Perera; Thanh-Truc Huynh; Irina A Lubensky; Arthur S Tischler; Richard Kvetnansky; Salvatore Alesci; John C Morris; Karel Pacak
Journal:  Clin Exp Metastasis       Date:  2009-01-25       Impact factor: 5.150

Review 8.  Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?

Authors:  Esther Korpershoek; Karel Pacak; Lucia Martiniova
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

9.  The prometastatic microenvironment of the liver.

Authors:  Fernando Vidal-Vanaclocha
Journal:  Cancer Microenviron       Date:  2008-05-17

10.  Strain-specific metastatic phenotypes in pheochromocytoma allograft mice

Authors:  Martin Ullrich; Josephine Liers; Mirko Peitzsch; Anja Feldmann; Ralf Bergmann; Ulrich Sommer; Susan Richter; Stefan R Bornstein; Michael Bachmann; Graeme Eisenhofer; Christian G Ziegler; Jens Pietzsch
Journal:  Endocr Relat Cancer       Date:  2018-10-05       Impact factor: 5.678

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.